Myocardial Infarction

• CLINICAL_TRIALS withdrawal · 2009-11-03
  Clinical Trial Update: A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN) [Phase 2]

  A Phase 2 safety and efficacy trial evaluating fondaparinux in percutaneous coronary intervention has been withdrawn.

• EMA withdrawal · 2009-04-23
  EMA Application withdrawn: Clopidogrel Teva Pharma (clopidogrel) — Teva Pharma B.V.

  The EMA application for Clopidogrel Teva Pharma (clopidogrel) has been withdrawn.

• CLINICAL_TRIALS withdrawal · 2009-01-09
  Clinical Trial Update: Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI [Phase 2]

  A Phase 2 study of ARC1779 in patients with acute myocardial infarction undergoing PCI was terminated.

• EMA withdrawal · 2008-05-27
  EMA Application withdrawn: DuoCover (clopidogrel;acetylsalicylic acid) — Bristol Myers Squibb Pharma EEIG

  EMA withdrew the application for DuoCover (clopidogrel and acetylsalicylic acid) from Bristol Myers Squibb Pharma EEIG.

• EMA withdrawal · 2008-05-27
  EMA Application withdrawn: DuoPlavin (clopidogrel;acetylsalicylic acid) — Sanofi Pharma Bristol-Myers Squibb

  EMA withdrew the application for DuoPlavin (clopidogrel and acetylsalicylic acid) by Sanofi Pharma Bristol-Myers Squibb.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2008-05-16
  EMA Withdrawn: Quixidar (fondaparinux sodium) — Glaxo Group Ltd.

  The EMA indicates withdrawal of Quixidar (fondaparinux sodium) from the market by Glaxo Group Ltd., covering indications including venous th…

• CLINICAL_TRIALS withdrawal · 2008-03-21
  Clinical Trial Update: COOL MI II: Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction [Phase 2, Phase 3]

  The COOL MI II trial evaluating cooling as an adjunctive therapy to percutaneous intervention in patients with acute myocardial infarction (…